Login
Companies $EVMN
$7.10 +$0.00 (0.0%) After hours
Evommune, Inc. logo

Evommune, Inc.

evommune.com

What Do They Do?

Develops drug candidates targeting chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis, for patients with these conditions.

How Do They Make Money?

Evommune earns money by licensing drug candidates to partners: partners pay upfront for the rights, may make further payments when development or sales milestones are reached, and may pay a share of product sales. Payments follow schedules set in each agreement.

FY2025 revenue

Who Are Their Customers?

Evommune grants license rights to partners through agreements; Maruho holds an exclusive license to develop and commercialize EVO756 in Japan.

Do Revenues Turn Into Profits?

No. It lost $68.9M in FY2025.

Operating income, FY2025
−624% of revenue
▼ −16% (Loss) vs FY2024 (−$70M, −1000%)
Net income, FY2025
−530% of revenue
▼ −3% (Loss) vs FY2024 (−$66.8M, −954%)
Free cash flow, FY2025
−590% of revenue
▼ −32% (Loss) vs FY2024 (−$58.3M, −833%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $10M in Q3 FY2025
Net income
▼ −148% (Loss)
vs −$12.5M in Q3 FY2025
  • Nov 4, 2026 Licensed EVO570 rights outside Greater China Hinova retained rights in Greater China; the agreement includes an upfront payment, milestone payments and royalties on future product sales.
  • Sep 8, 2026 Stopped developing EVO756 for atopic dermatitis after the trial missed endpoints Evommune plans to continue evaluating EVO756 for migraine prophylaxis.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support